Amylyx prices public offering of 17.5 million shares at $10 each

Amylyx Pharmaceuticals (AMLX) has priced an underwritten public offering of 17.5 million shares at $10 each, expecting to raise $175 million in gross proceeds to fund Avexitide commercial readiness, R&D, and general corporate purposes, following a year-to-date stock surge of over 178%. This capital raise coincides with the company's strategic decision to discontinue its ORION program for AMX0035 after a Phase 2b trial failed to demonstrate efficacy. Despite the program halt, analysts like Goldman Sachs view it as a "neutral-to-slightly positive strategic update," while Mizuho raised its price target to $12, citing an improved outlook and increased market share assumption for Avexitide, signaling a re-focus on the remaining pipeline's potential.

Analysis

Amylyx Pharmaceuticals (AMLX) is executing a significant strategic pivot, underscored by a $175 million public equity offering priced at $10 per share. This capital raise, which follows a more than 178% year-to-date stock surge, is explicitly intended to fund the commercial readiness of its drug candidate Avexitide. The financing coincides with the company's recent discontinuation of its ORION program for AMX0035 after the drug failed a Phase 2b trial. Despite the clinical setback, analyst sentiment is notably positive, framing the decision as a prudent reallocation of resources. Goldman Sachs maintained its Buy rating, viewing the program halt as a "neutral-to-slightly positive strategic update." More pointedly, Mizuho raised its price target on AMLX to $12.00 from $8.00, citing an improved outlook for Avexitide and increasing its market share assumption to 45%. This indicates that the market is valuing the sharpened focus on the remaining pipeline and the de-risking of the company's P&L from a failed program, with the new capital strengthening its ability to execute on its Avexitide strategy.

Key Decisions for Investors

• Investors should re-evaluate Amylyx based on the commercial potential of Avexitide for post-bariatric hypoglycemia, as this is now the primary value driver following the discontinuation of the ORION program.
• Consider the dilutive impact of the 17.5 million share offering against the strategic benefit of a strengthened balance sheet and dedicated funding for Avexitide's commercial launch, which analysts view as a net positive.
• Monitor future milestones related to Avexitide's commercial execution and market uptake, as the company's success is now heavily dependent on this single program, which carries inherent execution risk despite positive analyst sentiment.